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Abstract 
In pregnancies complicated by placental insufficiency and intrauterine growth restriction 
(IUGR), fetal glucose and oxygen concentrations are reduced, whereas plasma 
norepinephrine and epinephrine concentrations are elevated throughout the final third 
of gestation. Here we study the effects of chronic hypoxemia and 
hypercatecholaminemia on β-cell function in fetal sheep with placental insufficiency-
induced IUGR that is produced by maternal hyperthermia. IUGR and control fetuses 
underwent a sham (intact) or bilateral adrenal demedullation (AD) surgical procedure at 
0.65 gestation. As expected, AD-IUGR fetuses had lower norepinephrine concentrations 
than intact-IUGR fetuses despite being hypoxemic and hypoglycemic. Placental 
insufficiency reduced fetal weights, but the severity of IUGR was less with AD. Although 
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basal plasma insulin concentrations were lower in intact-IUGR and AD-IUGR fetuses 
compared with intact-controls, glucose-stimulated insulin concentrations were greater 
in AD-IUGR fetuses compared with intact-IUGR fetuses. Interestingly, AD-controls had 
lower glucose- and arginine-stimulated insulin concentrations than intact-controls, but 
AD-IUGR and AD-control insulin responses were not different. To investigate chronic 
hypoxemia in the IUGR fetus, arterial oxygen tension was increased to normal levels by 
increasing the maternal inspired oxygen fraction. Oxygenation of IUGR fetuses 
enhanced glucose-stimulated insulin concentrations 3.3-fold in intact-IUGR and 1.7-fold 
in AD-IUGR fetuses but did not lower norepinephrine and epinephrine concentrations. 
Together these findings show that chronic hypoxemia and hypercatecholaminemia have 
distinct but complementary roles in the suppression of β-cell responsiveness in IUGR 
fetuses. 
Placental insufficiency restricts the supply of oxygen and nutrients to the fetus and 
causes intrauterine growth restriction (IUGR) (1, 2). The resulting fetal hypoxemia and 
hypoglycemia provoke endocrine responses that lower plasma insulin concentrations 
(3,–5). High norepinephrine and epinephrine concentrations are a hallmark of both 
human and animal IUGR fetuses (6,–11). These high concentrations of catecholamines 
inhibit insulin secretion from pancreatic β-cells and may contribute to very low insulin 
concentrations in the IUGR fetus (12, 13). In addition, chronic elevation of 
norepinephrine has been shown to slow fetal growth and induce asymmetric growth of 
fetal tissues (14, 15). 
Our ovine model of placental insufficiency-induced IUGR reproduces many critical 
pathologies observed in the human IUGR fetus, including hypoglycemia, hypoxemia, 
and hypoinsulinemia (16, 17). In addition, plasma norepinephrine and epinephrine 
concentrations are elevated in both the human and sheep IUGR fetus in late gestation 
(9, 18). We have shown that elevated catecholamines play a major role in suppressing 
fetal insulin concentrations in the IUGR sheep fetus because an acute pharmacological 
blockade of adrenergic receptors increased insulin concentrations (19, 20). In fact, the 
adrenergic blockade exposed a compensatory gain in the insulin secretion response of 
IUGR fetuses because glucose-stimulated insulin concentrations increased to control 
levels despite substantially lower β-cell mass. We also observed compensatory insulin 
secretion responsiveness in sheep fetuses after a continuous 1-week infusion of 
norepinephrine (21). These findings demonstrate some of the functional adaptations in 
fetal β-cells in response to chronic hypercatecholaminemia. Other adaptations that we 
have observed in IUGR and norepinephrine-infused fetal sheep include lower adrenergic 
sensitivity in adipose tissue and skeletal muscle, a phenotype that persisted in young 
IUGR lambs (22,–24). 
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The evidence for catecholamine-induced adaptive responses in IUGR fetuses warrants 
further investigation. Thus, the present work was designed to test the two following 
hypotheses: 1) chronically elevated catecholamines in the IUGR fetus inhibit glucose-
stimulated insulin concentrations and are responsible for compensatory insulin secretion 
independently of hypoglycemia, hypoxemia, and hypoinsulinemia and 2) maternal 
oxygen therapy will increase blood oxygen content in the IUGR fetus to mitigate 
catecholamine concentrations and enhance glucose-stimulated insulin concentrations. 
To test these hypotheses, control and IUGR sheep fetuses, produced by hyperthermia-
induced placental insufficiency, were studied during late gestation after either a bilateral 
adrenal demedullation (AD) to eliminate adrenal catecholamine release or sham (intact) 
procedure. In vivo insulin secretion was determined under ambient laboratory 
conditions in all fetuses and after fetal arterial oxygen tension was increased to 
normoxemia in IUGR fetuses. 
 
Materials and Methods 
Fetal sheep preparations 
Animal procedures were approved by the Institutional Animal Care and Use Committee 
and were conducted in accordance with the Guide for the Care and Use of Laboratory 
Animals. All procedures were performed at The University of Arizona in facilities 
approved by the Association for Assessment and Accreditation for Laboratory Animal 
Care International. 
Columbia-Rambouillet cross-bred ewes carrying singleton pregnancies were purchased 
from Nebeker Ranch. Fetal number was confirmed by ultrasonography prior to 
treatment assignment. Ewes were assigned by a simple randomization method to one of 
two treatment groups, control or IUGR, at receipt. Placental insufficiency-induced IUGR 
fetuses (n = 20) were generated by exposing pregnant ewes to elevated ambient 
temperatures (40°C for 12 h; 35°C for 12 h; dew point 22°C) from 39 ± 1 day gestational 
age (dGA) to 93 ± 1 dGA (term 149 dGA) as described previously (19). Control fetuses (n 
= 17) were from ewes that were maintained at 25°C and pair fed to the average feed 
intake of IUGR ewes. All ewes were fed Standard-Bread alfalfa pellets (Sacate Pellet 
Mills) and had ad libitum access to water. A flow diagram of animal use is shown (Figure 
1). For a majority of animals used in this experiment, we have previously determined 
pancreatic endocrine cell mass and reported these findings along with fetal and organ 
weights in 2015 by Davis et al (15). The overlap by group includes six intact-controls, six 
AD-controls, six intact-IUGRs, and four AD-IUGR fetuses. 
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Figure 1. 
Flow diagram of animals use for experimental procedures. After eligibility was 
determined, pregnant ewes were assigned at random to an experimental treatment, 
IUGR or control, at 39 ± 1 day of gestation. Sham or bilateral AD surgical procedures 
were performed at 98 ± 1 day. One control and one IUGR fetus were lost during the first 
surgery due to complications. Two Intact-IUGR and three AD-IUGR fetuses died between 
the first and second surgeries. All fetuses survived the second surgical procedure when 
catheters were inserted. Two AD-control and two AD-IUGR fetuses were excluded from 
the analysis due to incomplete AD. The final groups are composed of fetuses that 
completed both ambient and oxygen reversal GSIS studies. 
At 98 ± 1 dGA (0.65 gestation) control and IUGR fetuses were assigned by a simple 
randomization method to undergo bilateral AD or a sham surgical procedure (intact) as 
previously described (25). Briefly, the fetal adrenal glands were isolated via 
retroperitoneal incisions and cauterized axially with an electrocautery needle. The 
current applied was sufficient to destroy the medulla, but portions of the adrenal cortex 
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remained intact, which was confirmed by immunohistochemistry At 121 ± 1 dGA, each 
fetus underwent a second surgical procedure to place indwelling arterial and venous 
catheters for blood sampling and infusion as described previously (9). At this time, a 
tracheal catheter was also surgically placed in each ewe (25, 26). Animals were allowed 
to recover for more than 5 days prior to the in vivo experimental procedures. The 
catheters were flushed daily with heparinized saline solution (100 U/mL heparin in 0.9% 
NaCl solution; Vedco, Inc). 
Ewes and fetuses were euthanized at 134 ± 1 dGA with an iv overdose of sodium 
pentobarbital (86 mg/kg) and phenytoin sodium (11 mg/kg; Euthasol; Virbac Animal 
Health). The fetus and placentomes were removed and weighed. Adrenal glands were 
collected, fixed in 4% paraformaldehyde, and embedded in optimum cutting 
temperature compound (Sakura Finetek USA) as previously described (25). 
Experimental design 
In vivo studies were performed on all fetuses to measure basal and glucose-stimulated 
insulin concentrations on two separate occasions (Figure 1). The first glucose-stimulated 
insulin secretion (GSIS) study was conducted under ambient laboratory conditions. After 
a 24- to 48-hour recovery period, a second GSIS study was performed under 
experimentally induced, steady-state reversal of fetal blood oxygenation conditions. 
Control fetuses were made hypoxemic by infusing 100% nitrogen gas into the maternal 
trachea catheter (∼5–10 L/h), and IUGR fetuses were made normoxemic (ie, to match 
arterial O2 pressure [PaO2] measured in control fetuses under ambient conditions) by 
infusing 100% oxygen gas. The targeted steady-state PaO2 was maintained for 60 
minutes prior to baseline blood sample collections and throughout the duration of the 
study period. Glucose-potentiated arginine-induced insulin secretion (GPAIS) was 
measured under ambient conditions only. 
Insulin secretion responsiveness 
Fetal insulin secretion responsiveness was measured with a square-wave hyperglycemic 
clamp as described previously (19, 27). Briefly, a continuous transfusion of maternal 
blood into the fetus (10 mL/h) was initiated 45 minutes prior to baseline sample 
collection to compensate for repeated sampling throughout the study. Three arterial 
blood samples were collected at 5-minute intervals under baseline steady-state 
conditions and averaged to generate basal period means. Steady-state hyperglycemia 
was induced by an iv dextrose bolus (∼0.6 mmol/kg estimated fetal weight) followed by 
a constant iv infusion of 33% dextrose solution. Fetal plasma glucose concentration was 
measured at 5- to 10-minute intervals during the initial 30 minutes, and the dextrose 
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infusion rate was adjusted accordingly to achieve a steady-state fetal plasma glucose 
concentration of 3 ± 0.5 mmol/L, which produces maximal glucose-stimulated insulin 
concentrations in near-term fetal sheep (27). Steady-state conditions were confirmed 
during the sampling period when arterial plasma glucose concentrations varied less than 
±6% of the mean and showed no systematic trend with time. Thirty minutes after 
steady-state hyperglycemia was achieved, three blood samples were collected at 5-
minute intervals and averaged to generate hyperglycemic period means. 
Maximal fetal insulin secretion responsiveness, an assessment of readily-releasable 
insulin, was measured by glucose-potentiated arginine-induced insulin secretion, as 
described previously (28, 29). Fetal blood samples were collected 5, 15, and 30 minutes 
after an arginine bolus (0.5 mmol/kg estimated fetal weight; Sigma-Aldrich Co), and the 
area under the curve was calculated in GraphPad Prism 6.01 (GraphPad Software, Inc). 
Blood and plasma analysis 
Fetal arterial blood (∼1.5 mL) was collected in EDTA-lined syringes (Sigma-Aldrich Co) 
and divided into two tubes, one of which was mixed to a final concentration of 0.5 mM 
EDTA and 0.33 mM reduced glutathione for catecholamine measurements. Plasma from 
both samples was separated by centrifugation (14 000 × g; 2 min). Glucose and lactate 
concentrations were determined in a small volume of plasma with a YSI model 2700 
SELECT Biochemistry Analyzer (Yellow Springs Instruments), and the remaining plasma 
was stored at −80°C. Additional fetal blood (∼200 μL) was collected in heparin-lined 
syringes (Elkins-Sinn, Inc), and blood gases, pH, hematocrit, and oximetry were analyzed 
with an ABL 720, (temperature corrected to 39.1°C; Radiometer). 
Plasma hormone concentrations were determined by an ELISA for insulin (Ovine Insulin 
ELISA; ALPCO Diagnostics; sensitivity 0.07 ng/mL; intra- and interassay coefficients of 
variation, 3% and 6%, respectively), cortisol (Oxford Biomedical Research; sensitivity 10 
pg/mL; intra- and interassay coefficients of variation, 9% and 12%, respectively), 
norepinephrine (Labor Diagnostika Nord; sensitivity 25 pg/mL; intra- and interassay 
coefficients of variation, 6% and 14%, respectively), and epinephrine (Labor Diagnostika 
Nord; sensitivity 8.3 pg/mL; intra- and interassay coefficients of variation, 11% and 17%, 
respectively). 
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Immunohistochemistry (Table 1) 
Table 1. Antibody Table 
Peptide/Protein 
Target 
Antigen 
Sequence 
(if Known) 
Name of Antibody 
Manufacturer, 
Catalog Number, 
and/or Name of 
Individual Providing 
the Antibody 
Species Raised 
(Monoclonal or 
Polyclonal) 
Dilution 
Used 
Bovine P450c17  Antibovine P450c17 
A. J. Conley, University 
of California, Davis 
Rabbit 
polyclonal 
500 
Chromogranin A  
AntichromograninA 
(LK2H10 + PHE5) 
Abcam, ab715, lot 
871225 
Mouse 
monoclonal 
250 
Tissue sections (10 μm) of fetal adrenal glands were immunostained with rabbit 
antibovine P450c17 (1:500; a gift from A. J. Conley, University of California, Davis; [30]) 
and mouse monoclonal antichromogranin A (LK2H10+PHE5) (1:250; Abcam; ab715, lot 
871225) as described previously (25). Immunocomplexes were detected with affinity-
purified secondary antibodies conjugated to Alexa Fluor488 or Alexa Fluor594 (Jackson 
ImmunoResearch Laboratories). Fluorescence images were visualized on a Leica DM5500 
microscope system and digitally captured with a Hamamatsu Digital Camera ORCA 
flash4.0LT. 
Statistical analysis 
Fetal treatment groups in this study were intact-controls (n = 7), AD-controls (n = 7), 
intact-IUGR (n = 7), and AD-IUGR (n = 5). The fetal sex ratio (percentage males) was 57% 
for intact-control, 86% for AD-control, 71% for intact-IUGR, and 80% for AD-IUGR 
groups. Fetuses with incomplete adrenal demedullation, identified by their 
catecholamine response to hypoxemia, were excluded. Values are expressed as mean ± 
SE. After the second surgery, animals were assigned a new identification number that 
did not correspond with treatment or previous identification to facilitate blinding and 
eliminate bias in subsequent analyses. Fetal weights and GPAIS area under the curve 
were analyzed by a one-way ANOVA (four treatment groups) using the general linear 
means procedure of SAS software (version 9.4; SAS Institute), and differences were 
determined with a post hoc least significant difference test. Basal and hyperglycemic 
period means for biochemical, hematological, and hormone values were analyzed by an 
ANOVA using MIXED procedures with fetus as the random effect. Main effects for GSIS 
studies in ambient conditions were treatment, period, or their interaction. The main 
effects for reverse oxygen tension study were treatment, period, and study, and by 
experimental design the interactions for treatment by period or treatment by study were 
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analyzed. Fetal sex was included as a variable in the GSIS ANOVA but removed from the 
model because no significant effect was found. Significant differences reported are P ≤ 
.05. 
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Results 
Immunofluorescent staining of fetal adrenal glands 
Immunostaining of the fetal adrenals identified successful depletion of the adrenal 
medulla but not cortex in AD fetuses (Figure 2). Adrenal gland in intact-IUGR fetuses 
have similar areas of adrenal cortex and medulla compared with intact-controls. 
 
 
Figure 2. 
 
Immunofluorescent staining of fetal adrenal glands. Fetal adrenal glands were 
immunostained with rabbit antibovine P450c17 (Alexa Fluor594; red), mouse antihuman 
chromogranin A (Alexa Fluor488; green), and 4′,6-diamidino-2-phenylindole (blue) to 
identify glucocorticoid-producing steroidogenic cells, chromaffin cells, and nuclear DNA, 
respectively. Overlays of representative photomicrographs are shown for intact-control 
(A), AD-control (B), intact-IUGR (C), and AD-IUGR fetuses (D). Negative controls are 
depicted in the insert for each adrenal gland. The bar in the lower right corner is 100 μm 
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Fetal growth restriction in IUGR fetuses 
Fetal and placental weights have been reported previously for a portion of the animals 
used in this study (15). Similar to the previous report, the average placental weights for 
these treatments showed that intact-IUGR fetuses (110.0 ± 11.9 g) and AD-IUGR fetuses 
(160.5 ± 27.4 g) were lighter (P < .05) than intact-controls (345.9 ± 18.4 g) and AD-
controls (280.4 ± 13.0 g). AD-control placentas weighed less than intact-controls, but 
AD-IUGR placentas tended to be heavier (P = .06) than intact-IUGR placentas. Intact-
IUGR fetuses were smaller than intact-controls (1.4 ± 0.2 kg vs 3.4 ± 0.1 kg, P < .05), and 
AD-IUGR fetuses weighed less than AD-controls (2.2 ± 0.4 kg vs 3.2 ± 0.2 kg, P < .05). 
Surgical AD had no effect on fetal weight in controls, but AD-IUGR fetuses were heavier 
than intact-IUGR fetuses. 
Adrenal demedullation increases GSIS in IUGR fetuses 
Under ambient laboratory conditions, PaO2 was lower in intact-IUGR and AD-IUGR 
fetuses than their respective controls during both basal and hyperglycemic periods but 
similar between IUGR groups (Figure 3A). During the basal period, PaO2 was 15% lower 
in AD-controls than intact-controls but was not different between the two during the 
hyperglycemic period. Arterial O2 content followed the same pattern as PaO2 (Table 2). 
 
11 
 
 
Figure 3. 
GSIS studies during ambient and reversed fetal oxygenation. Mean values for basal and 
hyperglycemic (HG) steady-state periods are presented for blood PaO2 and plasma 
concentrations of glucose, norepinephrine, and insulin. GSIS studies were performed in 
intact-control (n = 7), AD-control (n = 7), intact-IUGR (n = 7), and AD-IUGR fetuses (n = 
5). Under ambient laboratory conditions (panels A–D), significant treatment differences 
(P < .05) between means within the period are represented by different letters. The 
maternal inspired O2 fraction was increased to oxygenate IUGR fetuses during a second 
GSIS study (panels E–H). In control fetuses, the maternal inspired O2 fraction was 
decrease to produce fetal hypoxemia (panels I–L). The oxygen conditions for treatment 
groups are indicated above the representative column of panels. Comparisons were 
made between reversed and ambient studies as well as within the reversed oxygen 
tension study. *, Significant differences (P < .05) between GSIS studies; #, significant 
treatment difference within the GSIS study. 
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Table 2. Arterial Values in Ambient, Oxygenated, and Hypoxemic GSIS Studies 
Study Period 
Ambient Oxygen Tension 
 
Oxygenation 
 
Hypoxemia 
 
Intact-
Control (n 
= 7) 
AD-
Control 
(n = 7) 
Intact-
IUGR (n 
= 7) 
AD-
IUGR (n 
= 5) 
Intact-
IUGR (n 
= 7) 
AD-
IUGR (n 
= 5) 
Intact-
Control (n 
= 7) 
AD-
Control 
(n = 7) 
Basal         
    O2 
content, mmol/L 
3.8 ± 0.1a 3.0 ± 0.1b 2.1 ± 0.2c 
1.8 ± 
0.2c 
3.5 ± 0.2d 
3.4 ± 
0.3d 
1.3 ± 0.1d 1.2 ± 0.1d 
    PaCO2, 
mm Hg 
47.4 ± 0.5a 
51.6 ± 
0.6b 
51.3 ± 
1.3b 
54.4 ± 
1.1b 
49.9 ± 0.9 
54.1 ± 
1.3 
40.9 ± 0.7d 
46.4 ± 
1.3d,e 
    pH 
7.30 ± 
0.01a,b 
7.30 ± 
0.01a,b 
7.32 ± 
0.01a 
7.28 ± 
0.01b 
7.35 ± 
0.01d,e 
7.29 ± 
0.01 
7.28 ± 0.01 
7.28 ± 
0.01 
    
Hematocrit, % 
33.8 ± 0.5a 
35.7 ± 
1.3a,b 
42.5 ± 
1.5c 
40.9 ± 
1.9b,c 
38.5 ± 
1.7d 
37.5 ± 
2.0d 
36.1 ± 0.4d 
37.6 ± 
0.9d 
    
Bicarbonate, 
mmol/L 
21.2 ± 0.3 22.1 ± 0.3 22.2 ± 0.4 
21.3 ± 
0.3 
24.5 ± 
0.4d,e 
22.1 ± 
0.3d 
17.5 ± 0.7d 
18.6 ± 
0.5d 
    Lactate, 
mmol/L 
1.62 ± 
0.09a 
2.68 ± 
0.18a,b 
2.84 ± 
0.19a,b 
3.84 ± 
0.50b 
4.30 ± 
0.83d 
4.42 ± 
0.91 
8.15 ± 
0.96d 
8.20 ± 
0.83d 
Hyperglycemic         
    O2 
content, mmol/L 
3.5 ± 0.1a,f 2.9 ± 0.1b,f 
1.3 ± 
0.1c,f 
1.6 ± 
0.1c,f 
2.6 ± 0.2d 
3.0 ± 
0.3d 
1.2 ± 0.1d 1.2 ± 0.1d 
    PaCO2, 
mm Hg 
48.5 ± 0.6a 
52.4 ± 
0.9a,b 
54.5 ± 
0.8b,f 
56.5 ± 
1.2b,f 
54.5 ± 1.2 
56.4 ± 
1.2 
40.0 ± 0.6d 
48.8 ± 
1.2d,e 
    pH 
7.29 ± 
0.01a,f 
7.29 ± 
0.01a,f 
7.26 ± 
0.01a,b,f 
7.25 ± 
0.01b,f 
7.31 ± 
0.01d,e 
7.27 ± 
0.01 
7.16 ± 
0.02d 
7.16 ± 
0.03d 
    
Hematocrit, % 
33.4 ± 0.5a 
35.5 ± 
1.2a,b 
40.9 ± 
1.4b 
40.2 ± 
1.8b 
38.2 ± 
1.6d 
36.9 ± 
2.0d 
35.0 ± 0.4d 35.7 ± 0.9e 
    
Bicarbonate, 
mmol/L 
20.6 ± 0.3f 21.5 ± 0.2f 
19.9 ± 
0.4f 
20.0 ± 
0.3f 
23.1 ± 
0.4d 
21.7 ± 
0.4d 
13.3 ± 0.8d 
14.9 ± 
0.9d 
    Lactate, 
mmol/L 
2.18 ± 
0.09a,f 
3.05 ± 
0.15a,f 
5.70 ± 
0.34b,f 
5.23 ± 
0.57b,f 
4.38 ± 
0.62d 
4.30 ± 
0.76 
13.36 ± 
1.39d 
12.44 ± 
1.28d 
  
a-cLetter superscripts denote differences (P ≤ .05) within the period of the ambient oxygen tension study. 
dDifferences (P ≤ .05) within the period between GSIS studies (oxygenation or hypoxemia) vs ambient 
oxygen tension data. 
eTreatment differences (P ≤ .05) within steady-state periods for the reverse oxygen tension GSIS studies. 
fDifferences (P ≤ .05) between steady state periods within treatment group for the ambient GSIS study. 
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Glucose concentrations during the basal period were lower in intact-IUGR and AD-IUGR 
fetuses compared with intact-controls (Figure 3B). Basal glucose concentrations in AD-
IUGR fetuses were greater than intact-IUGR fetuses but still less than all control groups. 
Hyperglycemic glucose concentrations increased (P < .05) from basal, as expected, and 
were not different between treatments. 
Norepinephrine concentrations were approximately 5-fold greater in intact-IUGR fetuses 
compared with intact-control fetuses in both periods (Figure 3C). Adrenal demedullation 
at 98 dGA prevented high norepinephrine concentrations in AD-IUGR fetuses at 134 
dGA. In fact, AD-IUGR norepinephrine concentrations were not different from controls. 
Epinephrine concentrations were also higher (P < .05) in intact-IUGR fetuses (178.1 ± 
27.6 pg/mL) than in intact-controls, AD-controls, or AD-IUGR fetuses, which were below 
the detection limit. Basal cortisol concentrations were not different between treatment 
groups (Figure 4). 
 
 
Figure 4. 
Fetal cortisol concentrations in the basal period. Plasma cortisol concentrations were 
measured in intact-control (n = 7), AD-control (n = 7), intact-IUGR (n = 7), and AD-IUGR 
(n = 5) fetuses. Basal steady-state cortisol concentrations (mean ± SE) are presented for 
the ambient study and oxygenated (IUGR) or hypoxemic (control) studies. Different 
superscripts denote significant difference (P < .05). 
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Basal insulin concentrations were 79% lower in intact-IUGR fetuses and 56% lower in 
AD-IUGR fetuses compared with intact-controls, with AD-control fetuses being 
intermediate (Figure 3D). Basal insulin concentrations were not different between IUGR 
treatments. In all treatments, insulin concentrations increased (P < .001) in response to 
hyperglycemia. Glucose-stimulated insulin concentrations were 72% lower in intact-
IUGR fetuses compared with intact-controls. In AD-controls glucose-stimulated insulin 
concentrations were approximately 45% lower than in intact-controls but were not 
different from AD-IUGR fetuses. Glucose-stimulated insulin concentrations were 61% 
greater in AD-IUGR than intact-IUGR fetuses. 
Arterial PaCO2, pH, hematocrit, bicarbonate, and lactate values are presented (Table 1). 
Compared with intact-controls, PaCO2 was elevated in all other treatments. The pH was 
lower in AD-IUGR fetuses compared with intact-IUGR at basal. Hyperglycemia lowered 
blood pH and bicarbonate levels but increased lactate concentrations in all treatments. 
The hematocrit was elevated in intact-IUGR and AD-IUGR fetuses compared with intact-
controls, with AD-controls being intermediate at basal and hyperglycemic periods. 
Glucose-potentiated arginine-induced insulin secretion was observed in all treatment 
groups (Figure 5). After arginine administration, insulin concentrations were greater in 
intact-controls than in all other treatments, which were not different from one another. 
Area under the curve for GPAIS showed that intact-control fetuses (60.9 ± 4.7 μg/min · 
L) had a greater (P < .01) maximum insulin response than AD-controls (33.6 ± 5.5 
μg/min · L), intact-IUGR fetuses (27.1 ± 6.1 μg/min · L), and AD-IUGR fetuses (22.2 ± 2.1 
μg/min · L). 
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Figure 5. 
Glucose potentiated arginine-stimulated insulin secretion. Arginine was administered 
after the collection of the hyperglycemic samples. Plasma insulin concentrations (mean 
± SE) are present for the GPAIS period. The sampling times after the arginine bolus at 
time 0 are presented on the x-axis. Symbols identifying the four treatment groups are 
described in the legend for seven intact-control, seven AD-control, seven intact-IUGR, 
and five AD-IUGR fetuses. The asterisks denote significant difference (P < .05) between 
treatment groups. 
 
Oxygenation increases GSIS in IUGR fetuses 
In IUGR treatments maternal insufflation of 100% oxygen increased fetal PaO2 to levels 
observed in intact-control fetuses (Figure 3E). Similarly, blood O2 content increased in 
IUGR fetuses (Table 1). PaO2 and O2 content were not different between oxygenated 
study periods or treatments. 
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Basal and hyperglycemic glucose concentrations were not different between ambient 
(Figure 3B) and oxygenated GSIS studies (Figure 3F). Glucose concentrations also were 
not different between intact-IUGR and AD-IUGR fetuses during the basal or 
hyperglycemic period of the oxygenated GSIS study. 
Norepinephrine concentrations remained greater in intact-IUGR fetuses compared with 
AD-IUGR fetuses in both periods of the oxygenated GSIS study (Figure 3G). In intact-
IUGR fetuses, norepinephrine concentrations were increased in the oxygenated-
hyperglycemic period compared with the ambient-hyperglycemic period. AD-IUGR fetal 
norepinephrine concentrations were not different between studies for either period. 
Epinephrine concentrations remained high (P < .05) in intact-IUGR fetuses (177.0 ± 41.0 
pg/mL) compared with AD-IUGR fetuses, which remained undetectable. Basal cortisol 
concentrations increased in intact-IUGR fetuses, but not AD-IUGR fetuses, compared 
with the ambient study (Figure 4). 
Glucose-stimulated insulin concentrations were 3.3-fold greater (P < .05) in intact-IUGR 
fetuses and 1.7-fold greater (P < .05) in AD-IUGR fetuses during the oxygenated-
hyperglycemic period compared with their own ambient-hyperglycemic period (Figure 
3H). Basal insulin concentrations were not different between studies. No differences 
were found between IUGR treatments within the oxygenated GSIS study periods. 
Oxygenation increased blood pH in intact-IUGR fetuses during both periods but did not 
affect pH in AD-IUGR fetuses (Table 2). During oxygenation, basal and hyperglycemic 
bicarbonate concentrations increased in intact-IUGR and AD-IUGR fetuses. Oxygenation 
lowered the hematocrit in both IUGR treatments. In intact-IUGR fetuses, basal lactate 
concentrations increased with oxygenation but were lower with oxygenation during the 
hyperglycemic period. Lactate concentrations were not different between studies in AD-
IUGR fetuses. 
Hypoxemia-induced norepinephrine inhibits GSIS in control fetuses 
Maternal hypoxemia lowered blood PaO2 in control fetuses to the levels observed in 
IUGR fetuses at ambient conditions (Figure 3I). Blood O2 content was also decrease in 
control fetuses (Table 2). 
In intact-controls, hypoxemia increased basal and hyperglycemic glucose concentrations 
by 31% and 7%, respectively, compared with the ambient study (Figure 3J). Glucose 
concentrations were not different between hypoxemic and ambient GSIS studies for AD-
control fetuses or between intact-controls and AD-controls in the hypoxemic GSIS study 
periods. 
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Hypoxemia increased norepinephrine concentrations in intact-control fetuses by 6.8-
fold during the basal period and by 4.6-fold during the hyperglycemic period (Figure 
3K). Norepinephrine concentrations were unaffected by hypoxemia in AD-controls. 
Epinephrine concentrations were increased (P < .05) in intact-control fetuses (168.8 ± 
74.5 pg/mL) compared with AD-controls, which remained undetectable. Basal cortisol 
concentrations were increased in intact-controls compared with the ambient study but 
were unchanged in AD-control fetuses (Figure 4). 
In intact-control fetuses, hypoxemia decreased basal and hyperglycemic insulin 
concentrations, whereas AD-control insulin concentrations were unaffected (Figure 3L). 
Glucose-stimulated insulin concentrations were 1.7-fold greater in AD-controls than 
intact-controls during hypoxemia. 
Hypoxemia decreased PaCO2, but intact-control fetuses had lower PaCO2 levels 
compared with AD-controls (Table 2). Blood pH decreased with hypoxemia and 
hyperglycemia. Bicarbonate concentrations also decreased during hypoxemia. 
Hypoxemia increased the hematocrit in intact-control fetuses during both periods. In 
AD-control fetuses, the hematocrit increased during the basal-hypoxemic period but 
decreased during the hyperglycemic-hypoxic period, which was not different from the 
ambient hyperglycemic mean. Lactate concentrations were increased with hypoxemia 
and further increases with hyperglycemia but not different between control treatments. 
  
Discussion 
This study shows that the prevention of high-plasma catecholamines in the IUGR fetus 
augments glucose-stimulated insulin concentrations. These findings demonstrate a 
predominant role for elevated catecholamines in IUGR pathology that is independent of 
hypoxemia, hypoglycemia, and other fetal conditions. Moreover, adaptations to chronic 
adrenergic stimulation such as compensatory gain in β-cell responsiveness were not 
present in IUGR fetuses that had undergone adrenal demedullation. Experimental results 
for our second hypothesis demonstrate that increasing the maternal inspired O2 fraction 
increases blood O2 content in IUGR fetuses. However, acute oxygenation in intact-IUGR 
fetuses to normal levels did not lower plasma catecholamine concentrations but 
enhanced glucose-stimulated insulin concentrations by more than 3-fold. Moreover, 
fetal oxygenation improved maximal glucose-stimulated insulin concentrations in AD-
IUGR fetuses. These findings indicate that chronic fetal hypoxemia impairs pancreatic β-
cell responsiveness and demonstrate that oxygen tension exerts effects independent of 
catecholamines, which is not the case for control fetuses with acute hypoxemia. 
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Together our results indicate that prevention of chronic hypercatecholaminemia and 
normalization of oxygen tension can each independently potentiate glucose-stimulated 
insulin secretion in IUGR fetuses, and thus, chronic hypoxemia and 
hypercatecholaminemia likely play distinct but complementary roles in the suppression 
of glucose-stimulated insulin secretion in IUGR fetuses. 
Growing evidence indicates that inhibition of insulin secretion is mediated by several 
different regulatory factors and cellular mechanisms (31). In this study, IUGR reduced 
basal insulin concentrations by 79%, which is consistent with our previous findings (9, 
19). Catecholamines suppress insulin secretion, and we expected adrenal demedullation 
of IUGR fetuses to increase basal insulin concentrations in concert with lower 
catecholamine concentrations. However, we found that intact-IUGR and AD-IUGR 
fetuses had similar basal insulin concentrations despite substantially higher 
concentrations of catecholamines in the former. The lack of correlation between basal 
insulin and catecholamine concentrations demonstrates that low basal insulin results 
from hypoglycemia and hypoxemia, which were comparable between intact and AD-
IUGR fetuses and have been shown to directly impair β-cell function (9, 32, 33). 
In contrast to basal insulin concentrations, adrenal demedullation augmented glucose-
stimulated insulin concentrations in IUGR fetuses but blunted it in control fetuses. 
Adrenal demedullation did not improve maximal readily releasable insulin secretion in 
IUGR fetuses and, in fact, reduced insulin secretion in control fetuses by approximately 
50%. This is consistent with expectations that nonadrenergic factors influence insulin 
secretion in IUGR fetuses and provides a basis for the adrenal medulla in regulating 
insulin stimulus-secretion coupling in the healthy fetus. We have previously observed 
similar insulin secretion deficits in normal sheep fetuses after adrenal demedullation at 
0.82 gestation (25), which suggests that suppression of β-cell function in this study is 
not caused by limitations in β-cell development or maturation. An alternative 
explanation is that adrenal chromaffin cells may offer developing β-cells protection 
against temporary bouts of hypoglycemia and hypoxemia that are known to occur 
during pregnancy because β-cells have been shown to be especially susceptible to such 
stressors (32, 34, 35). 
Previous work in fetuses with chronically high catecholamines elucidated programming 
adaptations in adrenergic responsive tissues (22,–24). Our studies and others 
demonstrated acute pharmacological adrenergic receptor blockade enhanced the 
capacity for glucose-stimulated insulin secretion in IUGR fetuses (19, 20). This β-cell 
compensatory response to chronic catecholamine exposure was similar to phenomena 
previously reported in humans and animals after chronic adrenergic stimulation (21, 36,–
38). Our findings show that preventing chronic hypercatecholaminemia eliminates the 
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impetus for developing compensatory β-cells responsiveness. Future work will more 
clearly determine whether these adaptive responses in adrenergic signaling continue 
their role during the transition to postnatal life. 
The acute return of blood oxygen levels to normal restored glucose-stimulated insulin 
concentrations in IUGR fetuses to normal as well. It unexpectedly did so without 
decreasing catecholamines in intact-IUGR fetuses. Also, oxygenation potentiated 
glucose-stimulated insulin secretion in AD-IUGR fetuses, which lacked any 
catecholamine influence. In normal fetuses, monoamine oxidase and catechol-O-
methyltransferase enzymes are active in the liver and kidneys near term, yet placental 
clearance still accounts for approximately 70% of fetal catecholamine disappearance (39, 
40). In previous studies using fetal sheep with healthy placentas, iatrogenic 
catecholamine infusion or hypoxemia-induced acute elevations in fetal catecholamine 
concentrations promptly returned to resting values within an hour of removing the 
stimulus or source of exogenous catecholamines (41, 42). However, our model of IUGR 
produces substantial reductions in placental mass and functional capacity (43,–45), 
making it reasonable to postulate that placental catecholamine clearance is also 
impaired. In addition, we previously found that plasma norepinephrine concentrations 
remained elevated in normal fetal sheep 4 hours after terminating a week-long 
norepinephrine infusion (21), which indicates that chronic elevation of catecholamines 
may also stimulate increases in their own synthesis and secretion. 
The ability of acute oxygenation to improve glucose-stimulated insulin secretion in IUGR 
fetuses and more specifically in AD-IUGR fetuses shows that chronic hypoxemia exerts 
an independent role in limiting insulin secretion. Although normal fetuses are naturally 
hypoxemic relative to the maternal blood oxygen tension, increasing PaO2 in normal 
fetuses did not augment basal or stimulated insulin concentrations, indicating that 
oxygen is not limiting under normal conditions (12, 16). However, hyperglycemia 
increases oxygen consumption, which can lower intracellular oxygen tension and 
activate hypoxia inducible factor 1α (34, 46), and we show here that the 50% reduction 
in PaO2 observed in our IUGR fetuses limits insulin secretion in response to glucose, 
which may explain the intolerance to prolonged euglycemic correction previously 
observed in IUGR fetuses (47). Fetal hypoxemia in IUGR may also have a more direct 
influence on β-cells because perifusion experiments on rat and canine islets show that 
second-phase insulin secretion has a graded response to intermediate PaO2 levels and 
insulin secretion is inhibited by 50% at 27 mm Hg (48). In a previous study, pancreatic 
islet vascularity in the near-term IUGR fetus was similar to controls (49). This indicates 
inadequate oxygen delivery to islets is likely due to arterial hypoxemia caused by 
placental insufficiency. However, adaptation to chronic hypoxemia appears to be an 
important factor considering acute hypoxemia of AD-control fetuses was unaffected, 
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which is demonstrated here and in our previous study (25). Interestingly, reoxygenating 
islets after acute intermediate hypoxia elicited a transient spike in insulin secretion even 
though these IUGR fetuses have reduced β-cell mass (15, 48). Enhanced insulin secretion 
with oxygen in the IUGR fetus also appears to be transient because when the duration 
of oxygenation was extended to six hours in two intact-IUGR fetuses, the augmentation 
was lost. Additional work is required to define mechanisms for the pronounced rebound 
and its potential loss in insulin secretion in IUGR fetuses. 
In this study we also observed fluctuations in the hematocrit in response to the fetal 
oxygen status. Although mechanisms responsible for these differences were not directly 
investigated, we hypothesize that chronic hypoxemia in the IUGR fetus stimulate 
erythropoiesis (50, 51). However, differences in hematocrit have not been reported 
previously for this model (19, 52). Acute reversal in PaO2 produced reciprocal responses 
in IUGR and control fetal hematocrit that were not dependent on catecholamines. The 
acute alterations may represent vasomotor responses or atrial natriuretic peptide 
concentrations that affect plasma volume (53,–55). Nonetheless, the hematocrit is within 
an acceptable range demonstrated to support maximal oxygen delivery to fetal organs 
and tissues (56). 
In response to stress, like hypoxemia, cortisol is secreted from the adrenal gland and has 
been shown to slow fetal growth, alter carbohydrate metabolism, and promote 
maturation of fetal tissues (57,–59). In this study, cortisol concentrations were not 
different between the four treatment groups in ambient conditions, which is consistent 
with previous reports for this model of placental insufficiency-induced IUGR (60, 61) but 
not all reports (62, 63). Comparison between previous, independent IUGR reports 
indicate that cortisol concentrations associate positively with lactate concentrations, 
reflecting higher concentrations with greater severity of placental insufficiency (60). 
Therefore, intact-IUGR fetuses may perceive acute oxygenation as a stress because 
cortisol concentrations increased, which are also associated with higher lactate 
concentrations in this study and elevated norepinephrine concentrations during 
hyperglycemia in intact-IUGR fetuses. Although the presence of the fetal adrenal cortex 
was confirmed with P450c17 immunostaining, glucocorticoid synthesis in hypoxemic 
AD-control and oxygenated AD-IUGR fetuses was blunted compared with intact fetuses. 
We postulate that early gestational ablation of the adrenal medulla impaired the 
functional development of the adrenal cortex or hypothalamic-pituitary-adrenal axis 
because adrenal demedullation at later ages did not disrupt the cortisol response to 
hypoxemia (64). 
In the intact-IUGR fetus, oxygenation increased basal lactate concentrations but lowered 
lactate concentrations during the hyperglycemic period. Plasma lactate concentrations 
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are dependent on placental uptake, fetal production from glucose and nonglucose 
sources, and fetal consumption (65). We and others have proposed that a new 
equilibrium between lactate production and use is reached to support hepatic glucose 
production in IUGR fetuses (60, 66). IUGR fetuses develop a limited capacity for glucose 
oxidation, despite normal glucose use rates (60, 62). This limitation was associated with 
increased liver expression of pyruvate dehydrogenase kinase 4 and lactate 
dehydrogenase A to support intrahepatic lactate production for gluconeogenesis (62). 
Although not measured here, discrepancies between lactate production and use are 
apparent during oxygenation of intact-IUGR fetuses because plasma lactate 
concentrations increase at basal but did not increase further with hyperglycemia, unlike 
the ambient study. We have shown previously that although hyperglycemia improves 
rates of glucose use and oxidation, it also increases lactate concentrations (60). This 
suggests that in IUGR oxygenation alters the equilibrium of fetal lactate production and 
use during hypoglycemic conditions but allows rates of glucose oxidation to increase 
with hyperglycemia. The mechanic explanation for these findings remains unknown. 
In conclusion, our findings show that chronic fetal hypercatecholaminemia and 
hypoxemia independently contribute to reduced fetal growth and impaired insulin 
secretion in the IUGR fetus. Acutely increasing arterial oxygen tension in the IUGR fetus 
substantially augmented glucose-stimulated insulin secretion, regardless of whether 
fetal adrenal medullae were intact or ablated, which shows that fetal hypoxemia 
influences regulation of insulin stimulus-secretion function, even without adrenergic 
intercession. This study shows that, contrary to our original hypothesis, adrenergic 
activity may not overshadow the efficacy and safety of single-nutrient replacement 
therapies. However, based on detrimental outcomes of previous attempts at nutrient 
supplementation (47, 67,–70), we postulate that the first successful therapeutic 
intervention to improve fetal and neonatal outcomes in the context of placental 
insufficiency-induced IUGR will likely require the combination of nutrient 
supplementation (eg, glucose and amino acids), oxygen delivery, and endocrine 
modulation. These studies indicate that nutrient replacement strategies must take into 
account the modulation of the fetal endocrine profile and identify elevated plasma 
catecholamines as a critical factor that warrants further investigation in IUGR fetuses. 
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Footnotes 
Abbreviations:  
AD adrenal demedullation 
dGA days gestational age 
GPAIS glucose-potentiated arginine-induced insulin secretion 
GSIS glucose-stimulated insulin secretion 
IUGR intrauterine growth restriction 
PaO2 arterial O2 pressure. 
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